UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INWK, ESPR, PRTA, and PPG

NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

InnerWorkings, Inc. (NASDAQ:INWK)
Lead Plaintiff Deadline: July 9, 2018            
Class Period: August 11, 2015 – May 7, 2018

Allegations: InnerWorkings’ financial statements for the fiscal years ending December 31, 2015, 2016, and 2017, as well as all interim periods, contained errors that required restating; and as a result, InnerWorkings’ public statements were materially false and misleading at all relevant times.

Get additional information: http://www.kleinstocklaw.com/pslra-c/innerworkings-inc-2?wire=3.

Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Lead Plaintiff Deadline: July 6, 2018
Class Period: February 22, 2017 – May 1, 2018

Allegations: Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times.

Get additional information: http://www.kleinstocklaw.com/pslra-c/esperion-therapeutics-inc-2?wire=3.

Prothena Corporation (NASDAQ:PRTA)
Lead Plaintiff Deadline: July 16, 2018
Class Period: October 15, 2015 – April 20, 2018

Allegations: Prothena made materially false and/or misleading statements or failed to disclose that: relevant trial data showed that Prothena’s antibody NEOD001, designed to treat amyloid light chain amyloidosis (“AL amyloidosis”), was not an effective treatment; the Company made misleading comparisons of NEOD001’s “best response” rates against certain prior studies; and the Company touted Prothena’s ongoing Phase 1/2 study of NEOD001 as providing a strong basis for late-stage Phase 2b and Phase 3 studies of NEOD001, even though the full Phase 1/2 study data demonstrated that NEOD001 was not an effective treatment.

Get additional information: http://www.kleinstocklaw.com/pslra-c/prothena-corporation-2?wire=3.

PPG Industries, Inc. (NYSE:PPG)
Lead Plaintiff Deadline: July 19, 2018
Class Period: April 24, 2017 – May 10, 2018

Allegations: PPG’s consolidated financial statements for the year ended December 31, 2017 and quarterly financial statements for 2017 contained improper accounting entries and could not be relied upon; PPG failed to maintain adequate internal controls; and as a result, defendants’ public statements were materially false and misleading at all relevant times.

Get additional information: http://www.kleinstocklaw.com/pslra-c/ppg-industries-inc-2?wire=3.

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
                                                            
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com 

Share this post